Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a kidney and bladder cancers poster ...

Zusduri, which is delivered directly into the bladder in an out-patient procedure, is now the first and only medication approved by the US regulator to treat adults with recurrent low-grade ...

When people are suspected to have bladder cancer or have been diagnosed with bladder cancer, their doctors need to inspect the bladder closely and remove tissues for further examination. The removal ...

A grandfather who watched on screen as doctors removed a tumour from his bladder was home "within an hour" following the ...

Since Buckingham Palace confirmed King Charles had cancer in 2024, medical professionals around the globe have tried to ...

Shares of UroGen Pharma (URGN) shot up 9% on Friday morning after Guggenheim hiked its price target on the stock on the heels ...

The FDA has granted approval to UGN-102 for use in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer.

The U.S. Food and Drug Administration on Thursday approved UroGen Pharma's drug to treat a type of bladder cancer, providing an alternative treatment as opposed to traditional surgical procedures.

The FDA approved intravesical mitomycin in non–muscle-invasive bladder cancer as an nonsurgical alternative to transurethral ...

"For decades, TURBT has been the standard approach for bladder cancer treatment. That’s why innovative treatments like ZUSDURI are essential, especially for those adult patients with recurrent ...